Devimistat

From Wikipedia, the free encyclopedia
Devimistat
Devimistat.svg
Clinical data
Other namesCPI-613
Legal status
Legal status
  • Investigational
Identifiers
  • 6,8-Bis(benzylsulfanyl)octanoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.231.125 Edit this at Wikidata
Chemical and physical data
FormulaC22H28O2S2
Molar mass388.58 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
  • InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)
  • Key:ZYRLHJIMTROTBO-UHFFFAOYSA-N

Devimistat (INN; development code CPI-613) is an experimental anti-mitochondrial drug being developed by Cornerstone Pharmaceuticals.[1] It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML).

Devimistat's mechanism of action differs from other drugs, operating on the tricarboxylic acid cycle and inhibiting enzymes involved with cancer cell energy metabolism. A lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified FOLFIRINOX to treat various solid tumors and heme malignancies.

Regulation[edit]

The U.S. Food and Drug Administration (FDA) has designated devimistat as an orphan drug for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), peripheral T-cell lymphoma, and Burkitt's lymphoma, and given approval to initiate clinical trials in pancreatic cancer and AML.

Clinical trials[edit]

Clinical trials of the drug are underway including a Phase III open-label clinical trial[2] to evaluate efficacy and safety of devimistat plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

References[edit]

  1. ^ "CPI-613". Cornerstone Pharmaceuticals.
  2. ^ Philip PA, Buyse ME, Alistar AT, Rocha Lima CM, Luther S, Pardee TS, Van Cutsem E (October 2019). "A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas". Future Oncology. 15 (28): 3189–3196. doi:10.2217/fon-2019-0209. PMC 6854438. PMID 31512497.